| アブストラクト | We conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database on spontaneously reported adverse events to evaluate the association between anticancer drug therapy and hepatitis B infection. Reports of hepatitis B infection were retrieved from the FAERS database. The reporting odds ratio (ROR) was used to estimate the association between hepatitis B infection and various anticancer agents and drug combinations. We detected statistically significant risk signals of hepatitis B for 33 of 64 anticancer agents by ROR (26 cytotoxicity drugs and seven molecular-targeted drugs). We focused on molecular-targeted drugs and assessed the risk of hepatitis B from specific anticancer drug combinations. The frequency of hepatitis B infection was significantly high for drugs such as rituximab, bortezomib, imatinib, and everolimus. The addition of cyclophosphamide, doxorubicin, and fludarabine to drug combinations additively enhanced the frequency of hepatitis B infection. There were no reports on hepatitis B infection associated with trastuzumab or azacitidine monotherapy. However, trastuzumab-containing regimens (e.g., combinations with docetaxel or paclitaxel) were correlated with the incidence of hepatitis B infection, similar to azacitidine monotherapy. Our findings suggest that the concomitant use of anticancer drugs, such as trastuzumab, taxane, and azacitidine, may contribute to the risk of hepatitis B infection. The unique signals detected from the public database might provide clues to eliminate the threat of HBV in oncology. |
|---|
| ジャーナル名 | Cancer medicine |
|---|
| Pubmed追加日 | 2018/4/18 |
|---|
| 投稿者 | Sanagawa, Akimasa; Hotta, Yuji; Kataoka, Tomoya; Maeda, Yasuhiro; Kondo, Masahiro; Kawade, Yoshihiro; Ogawa, Yoshihiro; Nishikawa, Ryohei; Tohkin, Masahiro; Kimura, Kazunori |
|---|
| 組織名 | Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.;Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences,;Nagoya City University, Nagoya, Japan.;Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya;City University, Nagoya, Japan.;Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29663729/ |
|---|
